Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study - PubMed (original) (raw)

Clinical Trial

Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study

Marcia Cruz-Correa et al. Gastroenterology. 2002 Mar.

Abstract

Background & aims: Management of patients with familial adenomatous polyposis (FAP) can consist of colectomy with ileorectal anastomosis (IRA). Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients, although long-term use of this therapy has not been studied. We evaluated the long-term effectiveness and toxicity of sulindac in attempting to maintain retained rectal segments free of adenomas.

Methods: Twelve FAP patients (5 women), mean age 37.1 years, with IRA received sulindac (mean dosage, 158 mg/day) for a mean period of 63.4 +/- 31.3 months (range, 14-98 months). Number, size, and histologic grade of polyps, side effects, and medication compliance were assessed every 4 months.

Results: Seven of 12 patients (58%) remained in the study (6 of these polyp-free) for a mean of 76.9 +/- 27.5 months. Five of 12 patients (42%) withdrew from the trial after a mean follow-up period of 44 +/- 28 months (range, 14-89 months). A significant regression of polyp number was observed in all patients at 12 months (P = 0.039) and at a mean of 63.4 +/- 31.3 months (P = 0.006). Prevention of recurrence of higher-grade adenomas (tubulovillous, villous adenomas) was also observed (P = 0.004). At 35 months of follow-up, 1 patient developed stage III cancer in the rectal stump. The most common side effect was rectal mucosal erosions in 6 patients.

Conclusions: Long-term use of sulindac seems to be effective in reducing polyp number and preventing recurrence of higher-grade adenomas in the retained rectal segment of most FAP patients. Erosions at the IRA site can preclude adequate dose maintenance.

PubMed Disclaimer

Cited by

Nonsteroidal Anti-inflammatory Drugs for Chemoprevention in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis.
Farooq U, El Alayli A, Duvvuri A, Mansour R, Pasam RT, Malireddy S, Mustafa RA, Bansal A. Farooq U, et al. Gastro Hep Adv. 2023 Jun 10;2(7):1005-1013. doi: 10.1016/j.gastha.2023.05.009. eCollection 2023. Gastro Hep Adv. 2023. PMID: 39130765 Free PMC article. Review.
Black raspberry-mediated metabolic changes in patients with familial adenomatous polyposis associated with rectal polyp regression.
Huang YW, Chen HZ, Niu B, Wu W, Gao H, Yu J, Wang LS. Huang YW, et al. Food Front. 2024 Mar;5(2):259-266. doi: 10.1002/fft2.323. Epub 2024 Jan 29. Food Front. 2024. PMID: 38779578
Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes.
Kanth P, Hazel MW, Schell JC, Rutter J, Yao R, Mills AP, Delker DA. Kanth P, et al. Fam Cancer. 2024 Nov;23(4):479-489. doi: 10.1007/s10689-024-00370-7. Epub 2024 Apr 12. Fam Cancer. 2024. PMID: 38609520 Free PMC article.
Chemoprevention in Inherited Colorectal Cancer Syndromes.
Gilad O, Muller C, Kupfer SS. Gilad O, et al. Clin Colon Rectal Surg. 2023 Jul 19;37(3):172-179. doi: 10.1055/s-0043-1770384. eCollection 2024 May. Clin Colon Rectal Surg. 2023. PMID: 38606042 Free PMC article. Review.
Berries vs. Disease: Revenge of the Phytochemicals.
Lamenza FF, Upadhaya P, Roth P, Shrestha S, Jagadeesha S, Horn N, Pracha H, Oghumu S. Lamenza FF, et al. Pharmaceuticals (Basel). 2024 Jan 9;17(1):84. doi: 10.3390/ph17010084. Pharmaceuticals (Basel). 2024. PMID: 38256917 Free PMC article. Review.

Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study - PubMed (original) (raw)